Relevance of serum sclerostin concentrations in critically ill patients
Standard
Relevance of serum sclerostin concentrations in critically ill patients. / Koch, Alexander; Weiskirchen, Ralf; Ludwig, Sebastian; Buendgens, Lukas; Bruensing, Jan; Yagmur, Eray; Baeck, Christer; Herbers, Ulf; Trautwein, Christian; Tacke, Frank.
In: J CRIT CARE, Vol. 37, 02.2017, p. 38-44.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Relevance of serum sclerostin concentrations in critically ill patients
AU - Koch, Alexander
AU - Weiskirchen, Ralf
AU - Ludwig, Sebastian
AU - Buendgens, Lukas
AU - Bruensing, Jan
AU - Yagmur, Eray
AU - Baeck, Christer
AU - Herbers, Ulf
AU - Trautwein, Christian
AU - Tacke, Frank
N1 - Copyright © 2016 Elsevier Inc. All rights reserved.
PY - 2017/2
Y1 - 2017/2
N2 - PURPOSE: Sclerostin is a negative regulator of bone metabolism and associated with chronic morbidities. We investigated circulating sclerostin in critically ill patients.METHODS: A total of 264 patients (170 with sepsis) were studied prospectively upon admission to the medical intensive care unit (ICU) and on day 7. Patients' survival was followed for up to 3 years.RESULTS: Sclerostin serum levels were significantly elevated in critically ill patients at ICU admission compared with 99 healthy controls. Unlike in healthy controls, sclerostin did not depend on sex or age of ICU patients. Sclerostin was associated with disease severity, independent of the presence of sepsis. Sclerostin levels increased during the first week of treatment at the ICU but were not a predictor of mortality. Sclerostin was elevated in patients with preexisting chronic kidney disease or liver cirrhosis, but was not related to diabetes, obesity, or cardiovascular disease. Circulating sclerostin in ICU patients correlated with biomarkers reflecting renal, hepatic and cardiac dysfunction, and biomarkers reflecting bone metabolism.CONCLUSION: Serum sclerostin concentrations are significantly elevated in critically ill patients, linked to renal or hepatic organ failure, and associated with bone resorption markers, supporting its value as a potential tool for the assessment of ICU-related metabolic bone disease.
AB - PURPOSE: Sclerostin is a negative regulator of bone metabolism and associated with chronic morbidities. We investigated circulating sclerostin in critically ill patients.METHODS: A total of 264 patients (170 with sepsis) were studied prospectively upon admission to the medical intensive care unit (ICU) and on day 7. Patients' survival was followed for up to 3 years.RESULTS: Sclerostin serum levels were significantly elevated in critically ill patients at ICU admission compared with 99 healthy controls. Unlike in healthy controls, sclerostin did not depend on sex or age of ICU patients. Sclerostin was associated with disease severity, independent of the presence of sepsis. Sclerostin levels increased during the first week of treatment at the ICU but were not a predictor of mortality. Sclerostin was elevated in patients with preexisting chronic kidney disease or liver cirrhosis, but was not related to diabetes, obesity, or cardiovascular disease. Circulating sclerostin in ICU patients correlated with biomarkers reflecting renal, hepatic and cardiac dysfunction, and biomarkers reflecting bone metabolism.CONCLUSION: Serum sclerostin concentrations are significantly elevated in critically ill patients, linked to renal or hepatic organ failure, and associated with bone resorption markers, supporting its value as a potential tool for the assessment of ICU-related metabolic bone disease.
KW - Adolescent
KW - Adult
KW - Aged
KW - Aged, 80 and over
KW - Biomarkers/blood
KW - Bone Diseases, Metabolic/blood
KW - Bone Morphogenetic Proteins/blood
KW - Cardiovascular Diseases/blood
KW - Case-Control Studies
KW - Critical Care
KW - Critical Illness/mortality
KW - Diabetes Mellitus/blood
KW - Female
KW - Genetic Markers
KW - Humans
KW - Intensive Care Units
KW - Liver Cirrhosis/blood
KW - Male
KW - Middle Aged
KW - Mortality
KW - Obesity/blood
KW - Prognosis
KW - Prospective Studies
KW - Renal Insufficiency, Chronic/blood
KW - Sepsis/blood
KW - Young Adult
U2 - 10.1016/j.jcrc.2016.08.019
DO - 10.1016/j.jcrc.2016.08.019
M3 - SCORING: Journal article
C2 - 27621111
VL - 37
SP - 38
EP - 44
JO - J CRIT CARE
JF - J CRIT CARE
SN - 0883-9441
ER -